

Characterization of a Second Bovine Rotavirus Serotype

By

H. BRÜSSOW¹, S. MARC-MARTIN¹, W. EICHHORN²,
J. SIDOTI¹, and V. FRYDER¹

¹ Nestlé Research Department, Nestec Ltd., Vevey, Switzerland

² Institute of Medical Microbiology, Infectious and Epidemic Diseases,
Veterinary Faculty, University of Munich, Federal Republic of Germany

With 6 Figures

Accepted October 13, 1986

Summary

Bovine rotavirus (BRV) V1005 was characterized by two-way cross-neutralization tests as a second serotype of BRV. Virions and inner shell particles of 65 nm and 55 nm diameter respectively, and empty capsids of 65 nm and 55 nm diameter were separated by density gradient centrifugation. Three polypeptides of molecular weight 60,000, 36,000 and 28,000 (minor protein) could be identified in the outer shell of virions and in the larger empty capsids. Inner shell particles contained three polypeptides of molecular weight 105,000, 83,000 and 43,000. Both sizes of empty capsids showed two polypeptides of molecular weight 75,000 and 55,000 not found in virions. Pulse-labelling of infected cells revealed eight major and three minor intracellular viral polypeptides. Viral polypeptide synthesis started at about 6 hours p.i. and correlated in time with double-stranded RNA synthesis. As soon as viral polypeptide synthesis was detectable, newly synthesized viral polypeptides were incorporated into intracellular viral particles. Radioactive viral polypeptides appeared without a longer lag period in extracellular viruses from 6 hours p.i. onwards.

Introduction

Rotaviruses are a major cause of acute viral diarrhoea in a number of mammalian and avian species (9, 25). Several serotypes have been identified among rotaviruses from children (2, 36), calves (5, 16, 27, 30, 33, 35), foals (13), piglets (3), mice (12) and avian species (26). In calves about 90 per cent of rotavirus isolates belong to one serotype represented by

bovine rotavirus (BRV) UK (33, 35). Two other serotypes of BRV have been described (5, 16, 27, 30, 33, 35). Prototype 1 BRV UK has been well characterized (6, 21, 23, 24, 28, 34), but detailed information about other serotypes of BRV is scarce (31). In this report we give a biochemical description of the extracellular viral particles of BRV V 1005, which belongs to a second serotype of BRV, and its replication cycle in MA-104 cells.

Materials and Methods

Viruses

BRV UK, BRV NCDV, BRV V 1005 and simian rotavirus SA-11 were obtained from Prof. Bachmann (Institute of Medical Microbiology, Infectious and Epidemic Diseases, Veterinary Faculty, University of Munich, Federal Republic Germany). BRV V 1005 was isolated in his laboratory (1).

Tissue Culture

MA-104 cells were grown in 840 cm² disposable glass roller bottles (Flow laboratories) in minimal essential medium containing 10 per cent foetal bovine serum and maintained after inoculation in medium 199 containing 10 per cent tryptose phosphate and 10 µg/ml porcine pancreatic trypsin (Flow laboratories cat. No. 16-893). BRV V 1005 was treated with 20 µg/ml of trypsin at 37°C for 30 minutes before inoculation. Cells were inoculated at a multiplicity of infection of 4 TCID₅₀ per cell. Infectivity titrations were done according to BACHMANN and HESS (1).

Extracellular Rotavirus Purification and Electron Microscopy

Extracellular rotavirus particles were recovered from the cell-free culture supernatant of infected cells by high-speed centrifugation (90,000 × *g*, 2 hours, 4°C) through a 20 per cent sucrose cushion. They were further purified by CsCl equilibrium centrifugation (SB-405 rotor, International, 180,000 × *g*, 18 hours, initial density $\rho = 1388$ g/ml). The viral particles banding at the different density positions were recovered with a pasteur pipette, diluted with 0.9 per cent NaCl containing 10 mM CaCl₂ and pelleted by a further high-speed centrifugation (130,000 × *g*, 1 hour, 4°C). Alternatively, viruses were pelleted after dilution with 0.9 per cent NaCl containing 10 mM EDTA. The viral particles were deposited on copper grids coated with a formvar film and carbon. They were negatively stained with a 2 per cent solution of phosphotungstic acid, pH 7.0. Particles were viewed with a Philips EM 300 electron microscope at 80 kV accelerating voltage.

Radioactive Labelling and Isolation of Intracellular Viral Particles

The cells were labelled at 1-5, 5-9, 9-13 and 13-17 hours post infection (p.i.) with ³⁵S-methionine (7 µCi/ml, > 800 Ci/mmol, New England Nuclear) in methionine-free MEM containing 5 µg/ml trypsin. Alternatively, the cells were labelled at the same time intervals with ³H-uridine (7 µCi/ml, 80 Ci/mmol, Amersham). Immediately after the labelling period, the cells of one roller bottle were scraped off, washed in ice-cold PBS and resuspended in 50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl, 10 mM CaCl₂, 5 µg/ml soybean trypsin inhibitor (Sigma) and 0.5 per cent of the nonionic detergent Nonidet-P/40. The cellular extract was fractionated by differential centrifugation. Low-speed centrifugation (800 × *g*, 5 minutes, + 4°C) was followed by medium-speed centrifugation (10,000 × *g*, 30 minutes, + 4°C) and finally by high-speed centrifugation (130,000 × *g*, 1 hour, + 4°C). The high-speed pellet was checked by electron microscopy after negative

staining. 90 per cent of the material consisted of rotaviral particles. Some small membrane-derived debris was also found in this fraction.

For the comparison of intracellular viral proteins of different rotavirus strains, the infection medium was replaced at 12 hours p. i. with 20 ml methionine-free MEM to which 5 $\mu\text{Ci/ml}$ of ^{35}S -methionine (Amersham Ltd.) was added. After one hour labelling, cells were scraped from the roller surface with a rubber policeman. The cells were washed in phosphate buffered saline and lysed in the gel electrophoresis sample buffer (20).

Gel Electrophoresis

Protein electrophoresis was carried out in slab gels by Laemmli's method (20) using 13 per cent running and 3 per cent stacking gels. Molecular weights were calibrated using a mixture of ^{14}C -methylated polypeptides (Amersham), gels were fluorographed with Enlightning (New England Nuclear), dried and exposed on X-ray films (Y AR-5, Kodak).

Hyperimmunization of Mice and Guinea Pigs

Purified viral particles [approximately 50 μg proteins as determined by the method of BRADFORD (4) for each injection] were homogenized in Freund's complete adjuvant (first injection), in Freund's incomplete adjuvant (second injection), and in phosphate buffered saline (third injection). The viruses were administered intraperitoneally into mice and intramuscularly into guinea pigs. Animals were previously shown to be free of neutralizing antibodies to BRV UK, V 1005 and simian rotavirus SA-11. Sera were analysed 20 days after the last injection for neutralizing activity against 100 TCID₅₀ of BRV UK, BRV V 1005 and simian rotavirus SA-11 with the immunoperoxidase microtiter neutralization test of GERNA *et al.* (11). NT-titers are expressed as the reciprocal of the serum dilution reducing the number of infected cells by 90 per cent.

Column Chromatography

The cells were labelled with ^3H -uridine in the presence of 2 $\mu\text{g/ml}$ actinomycin D (Serva). Cells were lysed for 1 hour at 37°C in 1 ml TNE-buffer (50 mM Tris-HCl, pH 6.9; 1 mM EDTA, 100 mM NaCl) containing 0.8 per cent SDS (Sigma) and 500 $\mu\text{g/ml}$ proteinase K (Merck).

After three phenol extractions the RNA was precipitated with ethanol (overnight, -20°C). Cellulose column chromatography was performed as described by FRANKLIN (10). Each 1 ml fraction was counted in 10 ml Aquasol (NEN) in a liquid scintillation counter (Mark III, Searle).

Results

Neutralization Test

Neutralization tests with hyperimmune guinea pig and mouse sera showed that bovine rotavirus V 1005 was serologically distinct from bovine rotavirus UK, a prototype bovine rotavirus strain (Table 1). More than twenty times the limiting concentration of antisera which neutralized 100 TCID₅₀ of BRV UK failed to neutralize 100 TCID₅₀ of BRV V 1005 and more than 20 antibody units of sera to BRV V 1005 failed to neutralize 100 TCID₅₀ of BRV UK. BRV V 1005 is serologically as different from prototype BRV UK as is for example simian rotavirus SA-11. No significant serological interrelationship was detected between bovine rotavirus V 1005 and human

Table 1. *Serological differences between BRV UK and V 1005*

Antiserum to rotavirus	Animals ^a	Neutralizing antibody titer ^b to rotavirus			Homologous/ Heterologous titer ratio
		UK	V 1005	SA-11	
UK	Guinea pigs	> 12,800	200	100	> 64
V 1005	Guinea pigs	< 100	6,400	< 100	> 64
SA-11	Guinea pigs	100	< 100	> 12,800	> 128
Preimmune	Guinea pigs	< 100	< 100	< 100	
UK	Mice	> 12,800	< 100	< 100	> 128
V 1005	Mice	100	3,200	100	32
SA-11	Mice	< 100	< 100	3,200	> 32
Preimmune	Mice	< 100	< 100	< 100	

^a Mean of two animals

^b Reciprocal of highest serum dilution inhibiting the replication of 10^2 TCID₅₀ of indicated rotavirus in the neutralization test of GERNA *et al.* (11). Homologous titer in italics

rotavirus (HRV) Wa (serotype 1), HRV S-2 (serotype 2), simian rotavirus SA-11 (serotype 3) and HRV Hochi (serotype 4) (data not shown).

Four Particle Types of Extracellular Rotavirus

Extracellular BRV V 1005 grown in MA-104 cells was analyzed by CsCl density gradient centrifugation. Centrifugation resulted in the formation of four bands at buoyant densities of 1.31, 1.315, 1.36 and 1.38 g/ml. By electron microscopy the band at 1.31 g/ml was found to contain inner shell empty capsids of 55 nm diameter (Fig. 1 a). The band at 1.315 g/ml showed larger (65 nm) and less organized empty capsids (Fig. 1 b). The band at 1.36 g/ml contained 65 nm virions (Fig. 1 c) and the band at 1.38 g/ml gave 55 nm inner shell particles (Fig. 1 d). In a typical experiment 90 per cent of the infectivity applied to the gradient was associated with 65 nm virions; inner shell particles showed much lower infectivities and empty capsids were essentially non-infectious (e.g. $10^{7.5}$ TCID₅₀ at $\rho = 1.36$ g/ml versus 10^5 TCID₅₀ at $\rho = 1.38$ g/ml and 10^2 TCID₅₀ at $\rho = 1.31$ g/ml).

Polypeptide Composition of Extracellular Rotavirus

The four particle types separated by CsCl density gradients were analysed by SDS-polyacrylamide gel electrophoresis (Fig. 2). Virions are composed of 6 polypeptides: four major polypeptides of molecular weight 83,000, 60,000, 43,000 and 36,000, one minor polypeptide of molecular weight 105,000 and a very weakly labelled protein of molecular weight 28,000 (Fig. 2, lane c). In comparison with virions, inner shell particles lack the polypeptides of molecular weight 60,000, 36,000 and 28,000 (Fig. 2, lane d). The two types of empty capsids contain two polypeptides of molecular weight 75,000 and 55,000 (Fig. 2, lanes a, b) which are not found




Fig. 1. Electron micrographs of extracellular bovine rotavirus V1005 purified by CsCl density gradient centrifugation and negatively stained with 2 per cent phosphotungstic acid. *a* small empty capsids; *b* large empty capsids; *c* virions and *d* inner shell particles. Bar: 100 nm




Fig. 2. SDS-polyacrylamide gel electrophoresis of [^{35}S]-methionine-labelled structural polypeptides of *a* small empty capsids; *b* large empty capsids; *c* virions and *d* inner shell particles. Apparent molecular weights in thousands are indicated on the left-hand side, the nomenclature system of (23) for bovine rotavirus polypeptides is indicated on the right-hand side. Trypsin cleavage products of VP 4 are indicated by a dot

in virions. Otherwise they show the polypeptide composition of virions (Fig. 2, lanes B, c) or inner shell particles (Fig. 2, lanes a, d). Treatment of purified virions of BRV 1005 with EDTA removed the viral polypeptides of molecular weight 60,000 and 36,000 (Fig. 3), transforming the virions into inner shell particles (see also 7, 23).

Viral Protein Synthesis in Infected Cells

BRV V1005 induced the synthesis in infected MA-104 cells of polypeptides with molecular weights [minor polypeptides in parenthesis, VP nomenclature according to (23)] 105,000 (VP 1), 83,000 (VP 2), (80,000) (VP 3), 75,000 (VP 4), (55,000) (VP 5), 43,000 (VP 6), 36,000 (VP 7), 35,000 (VP 8), (34,000) (VP 9), 28,000 (VP 10), (20,000) (VP 11) (Fig. 4, lane b; Fig. 5 B, lanes d and e) which were not found in uninfected cells (Fig. 5 b, lane a). Intracellular polypeptides induced by BRV V1005 were compared to those induced by BRV Uk, BRV NCDV and simian rotavirus SA-11 (Fig. 4, lanes a to d). Slight molecular weight differences were observed for polypeptides with molecular weights 34,000 to 36,000. VP 11 was consistently barely detectable in V1005 infected cells.




Fig. 3. SDS-polyacrylamide gel electrophoresis of [³⁵S]-methionine labelled virions after sedimentation in the presence of 10 mM EDTA (a) or 10 mM CaCl₂ (b)




Fig. 4. Rotavirus polypeptide synthesis in MA-104 cells induced by BRV NCDV (a), BRV V1005 (b), BRV UK (c) and simian rotavirus SA-11 (d). Cells were labelled with [³⁵S]-methionine between 12 and 13 hours post-infection. Apparent molecular weights in thousands are indicated on the left-hand side, and the nomenclature system of McCRAE and FAULKNER-VALLE (23) for bovine rotavirus polypeptides on the right-hand side




Fig. 5. Analysis of the replication cycle of bovine rotavirus 1005 on MA-104 cells. *A* Growth curve or intracellular (\blacktriangle) and extracellular (\bullet) virus. *B* Polyacrylamide gel analysis of the kinetics of intracellular viral polypeptide synthesis. *a* uninfected cells; *b*–*e* infected cells labelled at the time periods L 1 to L 4 indicated below the growth curve (*A*). Viral polypeptides (*VP*) are numbered according to (23). *C* Polyacrylamide gel analysis of the kinetics of intracellular viral double-stranded RNA synthesis. *a* uninfected cells; *b*–*e* infected cells labelled at the time period L 1 to L 4 indicated below the growth curve (*A*). *D* CF-11 cellulose column chromatography of intracellular RNA (dpm in thousands) from uninfected MA-104 cells (\blacksquare) and cells labelled at 5–9 hours p.i. (\blacktriangle) and 9–13 hours p.i. (\bullet) with ^3H -uridine in the presence of actinomycin D. The thin line indicates the refraction index n_D of the elution buffer

Time Course of Rotavirus V1005 Replication in MA-104 Cells

When MA-104 cells were infected with bovine rotavirus V1005 at a multiplicity of 4 TCID_{50} /cell, infectious progeny virus appeared in the supernatant 5 hours p.i. and increased exponentially for up to 17 hours p.i. Before cell detachment, higher intracellular than extracellular titers of infectious

virus were found (Fig. 5, A). With cell detachment at 30 hours p.i. the majority of intracellular virus was released into the medium.

The time periods when labelling experiments were performed with ^{35}S -methionine or ^3H -uridine to correlate data on nucleic acid and protein synthesis in bovine rotavirus-infected cells with viral particle synthesis, are shown as L1 to L4 in Fig. 5, A.

In the first labelling period (L1: 1–5 hours p.i.) intracellular polypeptide synthesis was indistinguishable from uninfected cells (Fig. 5 B, lanes a and b). In the second and third labelling period (L2: 5–9, L3: 9–13 hours p.i.) viral polypeptide synthesis was evident on a background of cellular protein synthesis (Fig. 5 B, lanes c and d). With the onset of cytopathic effects (13 hours p.i.) exclusively viral polypeptides were synthesized (L4 period: 13–17 hours p.i.) (Fig. 5 B, lane e). Traces of double-stranded RNA were detected in the first labelling period (Fig. 5 C, lane b). Double-stranded RNA synthesis was clearly evident in the L2 period (Fig. 5 C, lane c), it increased within the L3 labelling period to remain stationary thereafter (Fig. 5 C, lanes d and e).

Fig. 5 D shows total intracellular RNA labelled with ^3H -uridine in the presence of actinomycin D, which was separated into single-stranded and double-stranded RNA on a CF-11 cellulose column. Actinomycin D treatment suppressed host RNA synthesis to background levels. Single-stranded RNA (fractions 20–25) and double-stranded RNA (fractions 33–38) were detected in the second labelling period and increased further in the third labelling period. Fractions 20–25 were susceptible to RNase A digestion




Fig. 6. Polyacrylamide gel analysis of the viral polypeptides found in intracellular (A) and extracellular (B) viral particles in the labelling periods L1–L4 (b–e). a uninfected cells. The apparent molecular weight of the viral polypeptides are indicated in thousands (K)

(0.1 µg/ml, 0.1 M NaCl, 37°C, 1 hour), whereas fractions 33–38 were resistant (data not shown).

Neither extracellular nor intracellular viral particles were synthesized in the first labelling period (Fig. 6 A, B, lane b respectively). From the second labelling period onwards newly synthesized intracellular and extracellular particles were detected (Fig. 6 A, B, lane c respectively) to reach maximal levels in the fourth labelling period.

Discussion

According to the criteria developed for serotype distinction of ECHO-viruses (8), rhinoviruses (18) and rotaviruses (36), bovine rotavirus V 1005 can be attributed to a second BRV serotype. It is serologically different from prototype BRV UK [serotype 6 according to (14)] and four human rotavirus serotypes [serotype 1–4 according to (14)]. Actually we do not know whether rotavirus V 1005 resembles serotype 5 (porcine rotavirus OSU, equine rotavirus H-1) or avian serotype 7 rotavirus defined by HOSHINO *et al.* (14) or whether it represents still another rotavirus serotype. In view of serologically distinct and still not classified rabbit (32) and mouse (12) rotaviruses, the number of rotavirus serotypes in mammalian species may be reasonably greater than the 6 serotypes defined by HOSHINO (14).

The outer shell proteins are the most relevant for the serological distinction of BRV (17, 19, 22, 29, 31). Of the three polypeptides identified in the outer shell of BRV 1005 that of molecular weight 36,000 and corresponding to VP 7 (23) is the major protein, followed by a polypeptide of molecular weight 60,000. The polypeptide of 28,000 molecular weight is only a minor component. A similar polypeptide composition was reported for the outer shell of BRV UK (34) and BRV NCDV (22). Some authors have described a further outer shell protein of BRV with molecular weight similar to that of VP 7 (6, 19, 21), whilst others have attributed this protein to the inner shell (23). NOVO *et al.* (28) and McCRAE and FAULKNER-VALLE (23) described a VP 4 protein as a prominent outer shell constituent. We have found this polypeptide only in empty capsids of BRV V 1005, and not in virions. The outer shell polypeptide of molecular weight 60,000 is not a primary gene product of BRV V 1005, because no homologous viral protein is found intracellularly. Therefore it probably represents the major tryptic cleavage product of VP 4, with the minor outer shell protein of molecular weight 28,000 found in V 1005 virions as the minor cleavage product (6).

The major tryptic cleavage product of rotavirus hemagglutinin was in the past referred to as VP 5 (6, 21, 22). However, the fifth gene of BRV UK codes for a VP 5 polypeptide which is only weakly labelled in cells (24). McCRAE and MCCORQUODALE (24) described this VP 5 as a non-structural polypeptide because it was not found in inner shell particles and virions.

Actually we detected in empty capsids, but not in inner shell particles or virions a polypeptide with the molecular weight of VP 5 (55,000 in our gel system). Further work must define the identity of this empty capsid-specific polypeptide.

The following conclusions can be drawn from the biochemical analysis of the replication cycle of V 1005 rotavirus in MA-104 cells. First, we found that viral polypeptide synthesis was correlated in time with viral double-stranded RNA synthesis. Second, a distinction of early and late synthesis products was not evident for intracellular V 1005 polypeptide synthesis, genomic RNA synthesis and intracellular and extracellular viral particles. Third, as soon as viral polypeptide synthesis was differentiable from the background of host protein synthesis, newly synthesized viral polypeptides were incorporated into intracellular particles. Fourth, newly synthesized viral polypeptides appeared without a longer lag period in extracellular viral particles even before any cytopathic effects were evident in the cell monolayer.

With the possible exception of the major outer shell protein VP 7, most intracellular viral polypeptides of BRV V 1005 were similar in molecular weight to those of BRV UK and NCDV. This contrasts to the extensive variations in molecular weights reported for intracellular viral polypeptides of rotaviruses from different species (34). However, the apparent molecular weight alone may not be a meaningful criterion to assess the relationship between rotaviral polypeptides of different rotavirus strains.

The similarity and variation in rotaviral structural polypeptides between prototype BRV UK and the second BRV serotype V 1005 defined in this paper is presently being investigated in our laboratory using biochemical and immunological methods.

Acknowledgement

We wish to thank the late Prof. P. Bachmann for the gift of BRV V 1005 and his encouragement of our work, Miss M. de Tiani for analysis of viral RNA on CF-11 columns, Dr. I. Horman for correcting the English text, Mrs. M. Weber and Mr. B. Pugin for photographic work and Mrs. C. Isom for careful typing of the manuscript.

References

1. BACHMANN PA, HESS RG (1981) Routine isolation and cultivation of bovine rotaviruses in cell culture. *Am J Vet Res* 42: 2149–2150
2. BEARDS GM, FLEWETT TH (1984) Serological characterization of human rotaviruses propagated in cell culture. *Arch Virol* 80: 231–237
3. BOHL EH, THEIL KW, SAIF LJ (1984) Isolation and serotyping of porcine rotaviruses and antigenic comparison with other rotaviruses. *J Clin Microbiol* 19: 105–111
4. BRADFORD M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72: 248–254

5. BRIDGER JC, BROWN JF (1984) Antigenic and pathogenic relationships of three bovine rotaviruses and a porcine rotavirus. *J Gen Virol* 65: 1151–1158
6. CLARK SM, ROTH JR, CLARK ML, BARNETT BB, SPENDLOVE RS (1981) Trypsin enhancement of rotavirus infectivity: mechanism of enhancement. *J Virol* 39: 816–822
7. COHEN J, LAPORTE J, CHARPILLENNE A, SCHERRER R (1979) Activation of RNA polymerase by calcium chelation. *Arch Virol* 60: 177–186
8. Committee on the ECHO Viruses (1955) Enteric cytopathogenic human orphan (ECHO) viruses. *Science* 122: 1187–1188
9. FLEWETT TH, WOODS GN (1978) The rotaviruses. *Arch Virol* 57: 1–23
10. FRANKLIN RM (1966) Purification and properties of the replicative intermediates of the RNA bacteriophage R17. *Proc Natl Acad Sci USA* 55: 1502–1511
11. GERNA G, BATTAGLIA M, MILENESI G, PASSAVANI N, PERCIVALLE E, CATTANEO E (1984) Serotyping of cell-culture-adapted subgroup 2 human rotavirus strains by neutralization. *Infect Immun* 43: 722–729
12. GREENBERG HB, VO PT, JONES R (1986) Cultivation and characterization of three strains of murine rotavirus. *J Virol* 57: 585–590
13. HOSHINO Y, WYATT RG, GREENBERG HB, KALICA AR, FLORES J, KAPIKIAN AZ (1983) Isolation, propagation and characterization of a second equine rotavirus serotype. *Infect Immun* 41: 1031–1037
14. HOSHINO Y, WYATT RG, GREENBERG HB, FLORES J, KAPIKIAN AZ (1984) Serotypic similarity and diversity of rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization. *J Infect Dis* 149: 694–702
15. HOSHINO Y, SERENO MM, MIDTHUN K, FLORES J, KAPIKIAN AZ, CHANOCK RM (1985) Independent segregation of two antigenic specificities (VP 3 and VP 7) involved in neutralization of rotavirus infectivity. *Proc Natl Acad Sci USA* 82: 8701–8704
16. IHARA T, SAMEJIMA T, KUWAHARA H, TAYIMA M (1983) Isolation of new serotypes of bovine rotavirus. *Arch Virol* 78: 145–150
17. KALICA AR, GREENBERG HB, WYATT RG, FLORES J, SERENO MM, KAPIKIAN AZ, CHANOCK RM (1981) Genes of human (strain Wa) and bovine (strain UK) rotaviruses that code for neutralization and subgroup antigens. *Virology* 112: 385–390
18. KAPIKIAN AZ, CONANT RM, HAMPARIAN VV, CHANOCK RM, CHAPPLE PJ, DICK EC, FENTERS JD, GWALTNEY JR, JM, HAMRE D, HOLPER JC, JORDAN JR, WS, LENNETTE EH, MELNICK JL, MOGABGAB WJ, MUFSON MA, PHILLIPS CA, SCHIEBLE JH, TYRRELL DAJ (1967) Rhinoviruses: a numbering system. *Nature* 213: 761–763
19. KILLEN HM, DIMMOCK NJ (1982) Identification of a neutralization-specific antigen of calf rotavirus. *J Gen Virol* 62: 297–311
20. LAEMMLI UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680–685
21. MATSUNO S, MIKAYAMA A (1979) Polypeptides of bovine rotavirus. *J Gen Virol* 43: 309–316
22. MATSUNO S, INOUE S (1983) Purification of an outer capsid glycoprotein of neonatal calf diarrhea virus and preparation of its antisera. *Infect Immun* 39: 155–158
23. McCRAE MA, FAULKNER-VALLE GP (1981) Molecular biology of rotavirus. I. Characterization of basic growth parameters and pattern of macro-molecular synthesis. *J Virol* 39: 490–496
24. McCRAE MA, MCCORQUODALE JG (1982) The molecular biology of rotaviruses. II. Identification of the protein-coding assignments of calf rotavirus genome RNA species. *Virology* 117: 435–443
25. McNULTY MS (1978) Rotaviruses. *J Gen Virol* 40: 1–18
26. McNULTY MS, ALLAN GM, TODD D, MCFERRAN JB, MCKILLOP ER, COLLINS DS, McCracken RM (1980) Isolation of rotaviruses from turkeys and chickens: demon-

- stration of distinct serotypes and RNA electropherotypes. *Avian Pathol* 9: 363-375
27. MURAKAMI Y, NISHIOKA N, HASHIGUCHI Y, KUNIYASHU C (1983) Serotypes of bovine rotaviruses distinguished by serum neutralization. *Infect Immun* 40: 851-855
 28. NOVO E, ESPARZA J (1981) Composition and topography of structural polypeptides of bovine rotavirus. *J Gen Virol* 56: 325-335
 29. OFFIT PA, BLAVAT G (1986) Identification of the two rotavirus genes determining neutralization specificities. *J Virol* 57: 376-378
 30. OJEH CK, SNODGRASS DR, HERRING AJ (1984) Evidence for serotypic variation among bovine rotaviruses. *Arch Virol* 79: 161-171
 31. SABARA M, GILCHRIST JE, HUDSON GR, BABIUK LA (1985) Preliminary characterization of an epitope involved in neutralization and cell attachment that is located on the major bovine rotavirus glycoprotein. *J Virol* 53: 58-66
 32. SATO K, INABA Y, MIURA Y, TOKUHISA S, MATUMOTO M (1982) Antigenic relationships between rotaviruses from different species as studied by neutralization and immunofluorescence. *Arch Virol* 73: 45-50
 33. SNODGRASS DR, OJEH CK, CAMPBELL I, HERRING AJ (1984) Bovine rotavirus serotypes and their significance for immunization. *J Clin Microbiol* 20: 342-346
 34. THOULESS ME (1979) Rotavirus polypeptides. *J Gen Virol* 44: 187-197
 35. WOODE GN, KELSO NE, SIMPSON TR, GAUL SK, EVANS LE, BABIUK L (1983) Antigenic relationship among some bovine rotaviruses: serum neutralization and cross-protection in gnotobiotic calves. *J Clin Microbiol* 118: 358-364
 36. WYATT RG, GREENBERG HB, JAMES WD, PITTMANN AL, KALICA AR, FLORES J, CHANOCK RM, KAPIKIAN AZ (1982) Definition of human rotavirus serotypes by plaque reduction assay. *Infect Immun* 37: 110-115

Authors' address: Dr. H. BRÜSSOW, Immunology Section, Nestlé Research Department, Nestec Ltd., Avenue Nestlé 55, CH-1800 Vevey, Switzerland.

Received June 13, 1986